Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.

NCT03596970 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Liver Transplantation

Interventions

DRUG: TAC withdrawal
DRUG: Everolimus with reduced TAC

Sponsor

Novartis Pharmaceuticals